首页> 外文期刊>The American heart journal >Incidence and correlates of major bleeding after percutaneous coronary intervention across different clinical presentations
【24h】

Incidence and correlates of major bleeding after percutaneous coronary intervention across different clinical presentations

机译:不同临床表现经皮冠状动脉介入治疗后大出血的发生率和相关性

获取原文
获取原文并翻译 | 示例
           

摘要

Background Bleeding after percutaneous coronary intervention (PCI) is identified as a strong predictor for adverse events, including mortality. This study aims to compare the incidence and correlates of post-PCI bleeding across different clinical presentations. Methods The study included 23,943 consecutive PCI patients categorized according to their clinical presentation: stable angina pectoris (n = 6,741), unstable angina pectoris (UAP) (n = 5,215), non-ST-segment elevation myocardial infarction (NSTEMI) (n = 8,418), ST-segment elevation myocardial infarction (STEMI) (n = 2,721), and cardiogenic shock (CGS) (n = 848). Results Severity of clinical presentation was associated with a greater use of preprocedural anticoagulation, glycoprotein IIb/IIIa inhibitors, and intraaortic balloon pump (IABP). TIMI-defined major bleeding increased with increasing severity of clinical presentation: stable angina pectoris, 0.7%; UAP, 1.0%; NSTEMI, 1.6%; STEMI, 4.6%; and CGS, 13.5% (P <.001). On multivariable analysis, CGS (odds ratio [OR], 4.67; 95% CI [2.62-8.34]), STEMI (OR, 3.39; 95% CI [2.07-5.55]), and NSTEMI (OR, 2.00; 95% CI [1.29-3.10]) remained correlated with major bleeding even after adjusting for baseline and procedural differences, whereas UAP did not. The multivariable model also identified the use of IABP, female gender, congestive heart failure, no prior PCI, increased baseline hematocrit, and increased procedure time as correlates for major bleeding. Conclusions In patients undergoing PCI, the worsening severity of clinical presentation corresponds to an increase in incidence of post-PCI major bleeding. The increased risk with CGS, STEMI, and NSTEMI persisted despite adjusting for more aggressive pharmacotherapy and use of IABP. Careful attention to antithrombotic pharmacotherapy is warranted in this high-risk population.
机译:背景经皮冠状动脉介入治疗(PCI)后出血被确定为不良事件(包括死亡率)的有力预测指标。这项研究旨在比较不同临床表现中PCI后出血的发生率和相关性。方法该研究包括23943名连续PCI患者,根据其临床表现进行了分类:稳定型心绞痛(n = 6741),不稳定型心绞痛(UAP)(n = 5215),非ST段抬高型心肌梗死(NSTEMI)(n = 8,418),ST段抬高型心肌梗死(STEMI)(n = 2,721)和心源性休克(CGS)(n = 848)。结果临床表现的严重程度与术前抗凝,糖蛋白IIb / IIIa抑制剂和主动脉内球囊泵(IABP)的使用有关。 TIMI定义的大出血随着临床表现的严重程度的增加而增加:稳定的心绞痛,0.7%; UAP,1.0%; NSTEMI,1.6%; STEMI,4.6%; CGS为13.5%(P <.001)。在多变量分析中,CGS(赔率[OR]为4.67; 95%CI [2.62-8.34]),STEMI(OR为3.39; 95%CI [2.07-5.55])和NSTEMI(OR为2.00; 95%CI) [1.29-3.10])即使调整了基线和程序差异,仍与大出血相关,而UAP没有。多变量模型还确定了IABP的使用,女性,充血性心力衰竭,没有事先PCI,基线血细胞比容增加和手术时间增加与大出血相关。结论在接受PCI的患者中,临床表现的恶化程度与PCI后大出血发生率的增加相对应。尽管已针对更积极的药物治疗和IABP的使用进行了调整,但CGS,STEMI和NSTEMI的风险增加仍然存在。在这一高风险人群中,应特别注意抗血栓药物治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号